As a board certified and licensed U.S. Physician, I have worked for the last 30 years to bring new medicines to patients in need.. I have served as a reviewer at the U.S. F.D.A., as a clinical investigator in an academic setting and, for the last 20 years, as a designer and leader for clinical trials at Pfizer. In my role as President and Chief Medical Officer for Oligomerix, I leverage my varied experiences to ensure that Oligomerix clinical studies are characterized by sound design and quality execution. My role overseeing clinical development programs for monoclonal antibodies directed against amyloid (bapineuzumab, ponezumab) as well as other pathophysiological targets (BACE, PDE-10) have prepared me to drive the clinical phase of this very promising tau protein-based program. For the last 5 years, I served as the Head for Pfizer’s internal Phase I Clinical Research Units (New Haven, CT, Brussels, Belgium). This experience gave me a thorough understanding of both the pitfalls and promise of early phase clinical research. My experience will help me to provide oversight for the clinical supplies manufacture process and ensure that the CMC activities are seamlessly integrated into the overall plan for the first in human study.